Unit of Dermatology and Skin Research Laboratory, Baruch Padeh Poria Medical Center, Tiberias, Israel.
Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
J Cosmet Dermatol. 2022 Dec;21(12):6549-6553. doi: 10.1111/jocd.15351. Epub 2022 Sep 20.
The impact of psoriasis on the outcomes of Coronavirus disease 2019 (COVID-19) is yet to be precisely delineated.
To assess the risk of COVID-19, COVID-19-associated hospitalization, and mortality among patients with psoriasis as compared with age-, sex-, and ethnicity-matched control subjects. In addition, we aim to delineate determinants of COVID-19-associated hospitalization and mortality in patients with psoriasis.
A population-based retrospective cohort study was performed to longitudinally follow patients with psoriasis and their matched controls with regard to COVID-19-related outcomes. The risk of COVID-19 infection, COVID-19-associated hospitalization, and mortality were assessed using uni- and multi-variable Cox regression analyses. Determinants of COVID-19-associated hospitalization and mortality were evaluated using multivariable logistic regression analysis.
The study population included 144 304 patients with psoriasis and 144 304 age- and sex-matched control individuals. Patients with psoriasis displayed a slightly elevated risk of SARS-CoV-2 infection (fully-adjusted HR, 1.05; 95% CI, 1.03-1.08; p < 0.001). Relative to controls, patients with psoriasis had comparable multivariate risk of COVID-19-associated hospitalization (fully-adjusted HR, 1.08; 95% CI, 0.99-1.18; p = 0.065) and COVID-19-associated mortality (fully-adjusted HR, 0.88; 95% CI, 0.73-1.05; p = 0.162). When evaluating individuals hospitalized due to COVID-19, patients with psoriasis were more likely to have type-2 diabetes mellitus (adjusted OR, 1.24; 95% CI, 1.03-1.50; p = 0.027) and obesity (adjusted OR, 1.37; 95% CI, 1.13-1.65; p = 0.001) relative to controls.
While patients with psoriasis are at a higher risk of contracting SARS-CoV-2 infection, they are not more susceptible to the complications of COVID-19.
银屑病对 2019 年冠状病毒病（COVID-19）结局的影响尚待准确描绘。
评估与年龄、性别和种族匹配的对照相比，银屑病患者 COVID-19 的发病风险、COVID-19 相关住院和死亡率。此外，我们旨在描绘银屑病患者 COVID-19 相关住院和死亡的决定因素。
进行了一项基于人群的回顾性队列研究，对银屑病患者及其匹配对照进行了 COVID-19 相关结局的纵向随访。使用单变量和多变量 Cox 回归分析评估 COVID-19 感染、COVID-19 相关住院和死亡率的风险。使用多变量逻辑回归分析评估 COVID-19 相关住院和死亡率的决定因素。
研究人群包括 144304 例银屑病患者和 144304 名年龄和性别匹配的对照个体。银屑病患者 SARS-CoV-2 感染的风险略有升高（完全调整后的 HR，1.05；95%CI，1.03-1.08；p<0.001）。与对照组相比，银屑病患者 COVID-19 相关住院的多变量风险相当（完全调整后的 HR，1.08；95%CI，0.99-1.18；p=0.065）和 COVID-19 相关死亡率（完全调整后的 HR，0.88；95%CI，0.73-1.05；p=0.162）。当评估因 COVID-19 住院的个体时，与对照组相比，银屑病患者更有可能患有 2 型糖尿病（调整后的 OR，1.24；95%CI，1.03-1.50；p=0.027）和肥胖症（调整后的 OR，1.37；95%CI，1.13-1.65；p=0.001）。
虽然银屑病患者感染 SARS-CoV-2 的风险较高，但他们不易发生 COVID-19 的并发症。
